How much profit has ESSA Pharma made this year?
ESSA Pharma has made -31.68 M USD this year.
ESSA Pharma Net Income 2024
ESSA Pharma Net Income
-31.68 M USD
Ticker
EPIX
ISIN
CA29668H7085
WKN
A2JKQ4
In 2024, ESSA Pharma's profit amounted to -31.68 M USD, a 19.18% increase from the -26.58 M USD profit recorded in the previous year.
The ESSA Pharma Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 151.63 |
| 2028e | -40.46 |
| 2027e | -70.71 |
| 2026e | -61.1 |
| 2025e | -41.18 |
| 2024e | -31.68 |
| 2023 | -26.58 |
| 2022 | -35.1 |
| 2021 | -36.81 |
| 2020 | -23.45 |
| 2019 | -12.76 |
| 2018 | -11.63 |
| 2017 | -4.5 |
| 2016 | -13.14 |
| 2015 | -9.36 |
| 2014 | -1.81 |
| 2013 | -1.03 |
| 2012 | -1.93 |
| 2011 | -0.98 |
ESSA Pharma Revenue, EBIT, Net Income CA29668H7085 · A2JKQ4
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ESSA Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ESSA Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ESSA Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ESSA Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ESSA Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ESSA Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ESSA Pharma’s growth potential.
ESSA Pharma Revenue, EBIT and net profit per share
| Date | ESSA Pharma Revenue | ESSA Pharma EBIT | ESSA Pharma Net Income |
|---|---|---|---|
| 2029e | 388.39 M undefined | 16.21 M undefined | 151.63 M undefined |
| 2028e | 109.88 M undefined | -106.46 M undefined | -40.46 M undefined |
| 2027e | 44.47 M undefined | -127.77 M undefined | -70.71 M undefined |
| 2026e | 5.68 M undefined | -80.6 M undefined | -61.1 M undefined |
| 2025e | 0 undefined | -58.25 M undefined | -41.18 M undefined |
| 2024e | 0 undefined | -41.81 M undefined | -31.68 M undefined |
| 2023 | 0 undefined | -32.14 M undefined | -26.58 M undefined |
| 2022 | 0 undefined | -36.97 M undefined | -35.1 M undefined |
| 2021 | 0 undefined | -37.16 M undefined | -36.81 M undefined |
| 2020 | 0 undefined | -23.93 M undefined | -23.45 M undefined |
| 2019 | 0 undefined | -12.15 M undefined | -12.76 M undefined |
| 2018 | 0 undefined | -11.03 M undefined | -11.63 M undefined |
| 2017 | 0 undefined | -16.06 M undefined | -4.5 M undefined |
| 2016 | 0 undefined | -18.7 M undefined | -13.14 M undefined |
| 2015 | 0 undefined | -15.84 M undefined | -9.36 M undefined |
| 2014 | 0 undefined | -2.94 M undefined | -1.81 M undefined |
| 2013 | 0 undefined | -1.02 M undefined | -1.03 M undefined |
| 2012 | 0 undefined | -1.92 M undefined | -1.93 M undefined |
| 2011 | 0 undefined | -980,000 undefined | -980,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 0 USD | -980,000 USD | -980,000 USD |
| 2012 | 0 USD | -1.92 M USD | -1.93 M USD |
| 2013 | 0 USD | -1.02 M USD | -1.03 M USD |
| 2014 | 0 USD | -2.94 M USD | -1.81 M USD |
| 2015 | 0 USD | -15.84 M USD | -9.36 M USD |
| 2016 | 0 USD | -18.7 M USD | -13.14 M USD |
| 2017 | 0 USD | -16.06 M USD | -4.5 M USD |
| 2018 | 0 USD | -11.03 M USD | -11.63 M USD |
| 2019 | 0 USD | -12.15 M USD | -12.76 M USD |
| 2020 | 0 USD | -23.93 M USD | -23.45 M USD |
| 2021 | 0 USD | -37.16 M USD | -36.81 M USD |
| 2022 | 0 USD | -36.97 M USD | -35.1 M USD |
| 2023 | 0 USD | -32.14 M USD | -26.58 M USD |
| 2024e | 0 USD | -41.81 M USD | -31.68 M USD |
| 2025e | 0 USD | -58.25 M USD | -41.18 M USD |
| 2026e | 5.68 M USD | -80.6 M USD | -61.1 M USD |
| 2027e | 44.47 M USD | -127.77 M USD | -70.71 M USD |
| 2028e | 109.88 M USD | -106.46 M USD | -40.46 M USD |
| 2029e | 388.39 M USD | 16.21 M USD | 151.63 M USD |
ESSA Pharma stock margins CA29668H7085 · A2JKQ4
The ESSA Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ESSA Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ESSA Pharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ESSA Pharma's sales revenue. A higher gross margin percentage indicates that the ESSA Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ESSA Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ESSA Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ESSA Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ESSA Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ESSA Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ESSA Pharma Margin History
| ESSA Pharma Gross margin | ESSA Pharma Profit margin | ESSA Pharma EBIT margin | ESSA Pharma Profit margin |
|---|---|---|---|
| 2029e | 0 % | 4.17 % | 39.04 % |
| 2028e | 0 % | -96.88 % | -36.83 % |
| 2027e | 0 % | -287.3 % | -159.01 % |
| 2026e | 0 % | -1,419.02 % | -1,075.66 % |
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2011 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2026e | 0 % | -1,419.02 % | -1,075.66 % |
| 2027e | 0 % | -287.3 % | -159.01 % |
| 2028e | 0 % | -96.88 % | -36.83 % |
| 2029e | 0 % | 4.17 % | 39.04 % |
ESSA Pharma Aktienanalyse
What does ESSA Pharma do?
ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding ESSA Pharma's Profit Margins
The profit margins of ESSA Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ESSA Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating ESSA Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
ESSA Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When ESSA Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about ESSA Pharma stock
How has the profit developed compared to last year?
The profit has increased by 19.18% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does ESSA Pharma publish its earnings?
ESSA Pharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of ESSA Pharma?
The profits of ESSA Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of ESSA Pharma?
You can learn more about the earnings of ESSA Pharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does ESSA Pharma pay?
Over the past 12 months, ESSA Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ESSA Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of ESSA Pharma?
The current dividend yield of ESSA Pharma is .
When does ESSA Pharma pay dividends?
ESSA Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ESSA Pharma?
ESSA Pharma paid dividends every year for the past 0 years.
What is the dividend of ESSA Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ESSA Pharma located?
ESSA Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ESSA Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ESSA Pharma from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.
When did ESSA Pharma pay the last dividend?
The last dividend was paid out on 9/19/2024.
What was the dividend of ESSA Pharma in the year 2023?
In the year 2023, ESSA Pharma distributed 0 USD as dividends.
In which currency does ESSA Pharma pay out the dividend?
The dividends of ESSA Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ESSA Pharma
Our stock analysis for ESSA Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ESSA Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
